A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Trial Profile

A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Umbralisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 12 May 2017 Planned End Date changed from 1 May 2017 to 1 Oct 2017.
    • 12 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
    • 04 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top